Krishnan Suma sold $75K of KRYS
Krishnan Suma (President, R&D) sold 247 shares of Krystal Biotech, Inc. (KRYS) at $303.17 on 2026-06-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a datapoint on insider liquidity/positioning but does not, by itself, introduce new fundamentals for KRYS.
Market read
Near-term trading impact is likely small; the main use is monitoring whether insider selling accelerates or is accompanied by other material company events.
What to watch
Traders may over-weight single Form 4s; better signal comes from clusters of sales/buys, changes in total insider ownership, or any concurrent operational/clinical updates.
Background
SEC Form 4 reports insider transactions; this one is an open-market sale by an officer/director/10% owner under a pre-arranged Rule 10b5-1 plan.
Ticker impact
Krystal Biotech disclosed an open-market sale by President, R&D Krishnan Suma under a pre-arranged 10b5-1 plan.
Likely limited immediate price impact; watch for follow-on insider activity or changes in selling pace.
The filing is a routine Form 4 open-market sale with stated 10b5-1 pre-arrangement, reducing informational content versus unscheduled sales.
Market effects
Minimal; this is company-specific insider activity without new clinical/regulatory or financial catalysts.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.
Key entities
- issuerKrystal Biotech, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderKrishnan Suma
President, R&D; officer/director/10% owner who sold 247 shares.
